Magle Chemoswed Holding Ab Cash Flow Conversion Efficiency
Magle Chemoswed Holding Ab cash flow conversion efficiency. Based on the latest financial reports, Magle Chemoswed Holding Ab (MAGLE) has a cash flow conversion efficiency ratio of -0.006x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.52 Million ≈ $-271.62K USD) by net assets (Skr395.84 Million ≈ $42.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Magle Chemoswed Holding Ab (2017–2025)
Cash flow conversion efficiency of Magle Chemoswed Holding Ab from 2017 to 2025. This chart illustrates how Magle Chemoswed Holding Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Magle Chemoswed Holding Ab stock price for real-time trading data and today's change.
Magle Chemoswed Holding Ab Cash Flow Conversion Ratio Explained
Magle Chemoswed Holding Ab cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Magle Chemoswed Holding Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Magle Chemoswed Holding Ab ranked by their cash flow conversion efficiency. Also see MAGLE market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
IMMERSION G. S.A. ZY 10
F:73W
|
3.367x |
|
Glass To Power SpA
PA:MLGLB
|
N/A |
|
CENTURION MINERALS L. NEW
F:XJC0
|
0.106x |
|
Reliance Industries Limited
IL:RIGD
|
N/A |
|
MCX Technologies Corp
V:MCX
|
0.047x |
|
Kermode Resources Ltd
V:KLM
|
0.087x |
|
MAPLE LEAF GREEN WORLD
F:4HV0
|
0.000x |
|
TrustBIX Inc
V:TBIX
|
0.061x |
Annual Cash Flow Conversion Efficiency for Magle Chemoswed Holding Ab (2017–2025)
The table below shows the annual cash flow conversion efficiency of Magle Chemoswed Holding Ab from 2017 to 2025. Review cash generation quality of Magle Chemoswed Holding Ab to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr395.84 Million ≈ $42.60 Million |
Skr-31.93 Million ≈ $-3.44 Million |
-0.081x | -286.53% |
| 2024-12-31 | Skr560.60 Million ≈ $60.33 Million |
Skr-11.70 Million ≈ $-1.26 Million |
-0.021x | -121.54% |
| 2023-12-31 | Skr158.22 Million ≈ $17.03 Million |
Skr15.33 Million ≈ $1.65 Million |
0.097x | +14.08% |
| 2022-12-31 | Skr146.77 Million ≈ $15.79 Million |
Skr12.47 Million ≈ $1.34 Million |
0.085x | -54.73% |
| 2021-12-31 | Skr138.79 Million ≈ $14.94 Million |
Skr26.04 Million ≈ $2.80 Million |
0.188x | +492.89% |
| 2020-12-31 | Skr116.12 Million ≈ $12.50 Million |
Skr-5.54 Million ≈ $-596.73K |
-0.048x | +23.40% |
| 2019-12-31 | Skr113.66 Million ≈ $12.23 Million |
Skr-7.08 Million ≈ $-762.46K |
-0.062x | -128.56% |
| 2018-12-31 | Skr50.67 Million ≈ $5.45 Million |
Skr11.06 Million ≈ $1.19 Million |
0.218x | -65.21% |
| 2017-12-31 | Skr42.98 Million ≈ $4.63 Million |
Skr26.96 Million ≈ $2.90 Million |
0.627x | -- |
About Magle Chemoswed Holding Ab
Magle Chemoswed Holding AB (publ), together with its subsidiaries, engages in research and development of pharmaceutical and medical device products in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; and benserazide hydrochloride… Read more